Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed... see more

NDAQ:LMNL - Post Discussion

Liminal BioSciences Inc. > Pritchard on possible new Fez/4050 announcement
View:
Post by stockbuphoon on Aug 18, 2021 10:11am

Pritchard on possible new Fez/4050 announcement

End of year target (which management always take longer than they estimate) for a new Fezagrapras indication. How many years cash do they have? Does the market believe anything this company does? 

In terms of the pipeline and where we're going, again, we're working very hard on this right now. As you know, the ongoing MAD study is progressing. We're almost at the end of that. By the time, we analyze the remainder of that data look at the additional preclinical work that we're looking at, at the moment with fezagepras. We would hope that we are in a position to provide further granularity on both where we're going with the fezagepras program, and indeed the timing and outlook for both the GPR84 and OXER1 programs in a similar sort of time frame. So, certainly before the end of this calendar year.

Comment by fatcashfast on Aug 18, 2021 10:59am
This post has been removed in accordance with Community Policy
Comment by stockbuphoon on Aug 18, 2021 11:52am
U're ? Only idiot who uses this shirt form is the pumper with 6 boardnames. and I do stand by my call of 4050 / fez being dead to this company (only) by December decision as they said they would have more to report on potential indication (or not) by end of year. do you think this stock would fall 90% on shorts alone? What is their new business milestone? Man, you're just plain ...more  
Comment by captsecord on Aug 18, 2021 1:04pm
This post has been removed in accordance with Community Policy
Comment by stockbuphoon on Aug 18, 2021 1:44pm
yes it could be alive but it's likely dead in December after we've spent another five months of cash. Then all you have is pre-clinical molecules which will take years to get to phase 1 human trials. There's a reason why the stock is trading at 10% of its high value.What about your $50 easy price target? Is that gonna hit by the end of the year? LOL
Comment by fatcashfast on Aug 18, 2021 2:02pm
This post has been removed in accordance with Community Policy
Comment by stockbuphoon on Aug 18, 2021 2:58pm
what happened to $50 easy, buddy? And why do you have to use 6 boardnames Newcamo Realstocky Tommyjones CaptSecord Mariadelapena fatcashfast to try to pump this turd? You say the exact same thing no matter what the price. 2x-3x from here on voucher cash and nothing. 2-3x on FDA approval and it fell under $4 within couple of days! And now it's at $2.30 and you're pumping even harder. You ...more  
Comment by stockbuphoon on Aug 18, 2021 11:49am
By the end of the year, they will have a decision on whether they have another indication for Fezagrapras or whether they shut it down after they analyze more PRECLINICAL data. So, this is new as they have all data on heart, Liver, kidney etc. If they decide to go ahead, they need to start a new trial design for a new indication and that's a ton of waiting and paperwork.  and why is ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities